|Bid||66.76 x 900|
|Ask||66.99 x 800|
|Day's Range||66.70 - 67.21|
|52 Week Range||42.48 - 67.21|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||19.28|
|Earnings Date||Feb 05, 2020|
|Forward Dividend & Yield||1.80 (2.70%)|
|Ex-Dividend Date||Dec 31, 2019|
|1y Target Est||70.60|
The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to make breaking announcements, went by without much fanfare ...
With politicians on both sides of the aisle calling for drug price controls, and a number of the Democratic candidates calling for "Medicare for all," it has been a challenging environment for a host of medical sectors, suggests income expert Chuck Carlson, editor of DRIP Investor.
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 15) 10X Genomics Inc (NASDAQ: TXG ) Aimmune Therapeutics ...
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
U.S. FDA Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo Plus Yervoy in First-Line Non-Small Cell Lung Cancer
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Biogen Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
What a difference a year makes. The start of the annual J.P. Morgan Healthcare investor conference in 2019 brought a double-header of giant deals. In 2020, there was almost nothing.
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $66.15, marking a +1.41% move from the previous day.
Joe Panetta knows that Union Square is the place where he has to be during the week of the J.P. Morgan Healthcare Conference, which starts Monday. Hotel rooms, many used exclusively for meetings, cost as much as $1,000 a night as 20,000-plus drug company, venture capital and investment banking personnel swarm Union Square. Any space is at a premium — reflected in the $300 price last year to sit at a table in the lobby of the Sir Francis Drake Hotel for three hours.
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.
Pharma giant Bristol-Myers Squibb deepened its cancer treatment partnership with Nektar Therapeutics on Friday — leading NKTR stock to pop to its highest point since August 2019.
Nektar Therapeutics shares leap as the company and Bristol-Myers said they would expand their partnership to develop a cancer treatment.